Immune Therapeutics, Inc. (OTC: IMUN) Recent News
Immune Therapeutics, Inc. Provides Shareholder Update on Food and Drug Administration (FDA) in relation to the Cytocom’s planned Phase 2 clinical trial of CYTO-201 for the treatment of SARS-CoV-2, the virus responsible for COVID-19.
Meanwhile, Immune Therapeutics today was notified by Cytocom Inc. where Immune holds a major equity stake of their successful Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) in relation to the Cytocom’s planned Phase 2 clinical trial of CYTO-201 for the treatment of SARS-CoV-2, the virus responsible for COVID-19. Based on the FDA’s feedback, Cytocom plans to revise the study protocol and quickly initiate enrollment.
“We are very excited by the progress that Cytocom has demonstrated to advance the work on Cyto -201 in the fight against the virus” stated Kevin Phelps, CEO of Immune. “We recognize that Cytocom’s success enhances Immune’s shareholder value. As such, we continue to look for opportunities to support their efforts and to find novel projects where we can consider direct collaboration”.
Noreen Griffin, Cytocom President, noted that Cytocom has proposed a randomized, Phase 2 study to evaluate the safety and efficacy of CYTO-201 as a treatment to slow or halt the progression of the SARS-CoV-2 infection from mild/moderate (stage 1-2A) to severe (stage 2B-3).
She indicated that the FDA provided guidance on Cytocom’s plans for the proposed Phase 2 trial, as well as expedited review paths and 505(b)(2) premarketing requirements for CYTO-201. Cytocom provided the agency with data from preclinical in vitro studies that demonstrated the potential of CYTO-201 to inhibit the replication of the SARS-CoV-2 virus in human lung cells. Further, Cytocom has demonstrated in previous human studies that CYTO-201 can dampen harmful inflammation and possibly promote protection from reinfection. These are particularly important features in the fight to tamp down the spread of COVID-19.
Michael Handley, Cytocom CEO, stated, “Our positive interactions with the FDA, combined with the expedited regulatory process, places CYTO-201 on an accelerated positive NDA submission path. This represents a significant milestone for Cytocom and patients suffering from the debilitating and life threatening consequences that stem from COVID-19.”
Immune Therapeutics, Inc. (OTC: IMUN) Video
Immune Therapeutics, Inc. (OTC: IMUN) Short Squeeze
Over the past twenty days of trading, Immune Therapeutics (OTCMKTS: IMUN), from June 04, 2020 to July 02, 2020 there is a potential Short Squeeze about to happen because of an increase in short volume over the past twenty days with very little cover volume.
Because of this the Squeeze Report trend indicator issued a Immune Therapeutics Short Squeeze.
Immune Therapeutics, Inc. (OTC: IMUN) Chart
This article is for the purposes of solicitation subscriptions for Trader Alert. The website Trader Alert expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. Trader Alert or it’s authors do not own any shares of Immune Therapeutics, Inc. (OTC: IMUN) and does not buy, sell, or trade any shares of IMUN. This article does not provide a professional analysis of a IMUN financial position. IMUN financial position and all other information regarding the featured Company should be verified directly with IMUN. Please read our full disclaimer for more detailed information.